We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for lenvatinib (as mesilate) (Eisai Australia Pty Ltd)
Active ingredients
lenvatinib (as mesilate)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Therapeutic area
Oncology